Pharma BD Deal Intelligence
Transformed Nycomed into a top-25 global pharma overnight, but its core acquired asset (pantoprazole/Protonix) hit the generic cliff within a year of close; the visible PE payoff came from the 2011 Takeda exit of the whole group, not cleanly from the Altana assets alone.
Full analysis, sources & comparables →Setbacks for ciclesonide (Alvesco) and roflumilast (Daxas) in the US 'took some of the lustre off' Altana's near-term pipeline, raising questions about…
Shareholder activists argued Altana management had under-invested in the pharma business and failed to develop successor products before pantoprazole's patent…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
EUR 4.5B / ~$5.7B. Acquired Jan 1, 2007 effective; deal announced 2006 closed early 2007. Pantoprazole, respiratory franchise. Source: Pharma Times, C&EN, PitchBook.
Transformed Nycomed into a top-25 global pharma overnight, but its core acquired asset (pantoprazole/Protonix) hit the generic cliff within a year of close; the visible PE payoff came from the 2011 Takeda exit of the whole group, not cleanly from the Altana assets alone.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nycomed / Altana Pharma AG (this deal) | 2007 | $4.5B | 58 |
| Nycomed / Altana Pharma AG | 2006 | $5.7B | 59 |
| Nycomed / Bradley Pharmaceuticals | 2007 | $346M | 48 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2007 deals · Nycomed deals